Articles

Addressing the 2011 Association of Community Cancer Centers annual meeting attendees, Timothy Tyler, PharmD, FCSHP, Director of Pharmacy Services at the Desert Regional Medical Center Comprehensive Cancer Center, Palm Springs, CA, outlined the considerable demands and complications that have been added to oncology care with the introduction of the Risk Evaluation and Mitigation Strategies (REMS) program for high-risk drugs.

Chairpersons of the various National Comprehensive Cancer Network (NCCN) tumor panels presented clinical practice updates at the recent 16th Annual Conference of the NCCN. Key updates, and relevant discussions, are highlighted.

Applying its priority review route, the FDA approved the biologic medication ipilimumab (Yervoy; Bristol-Myers Squibb) as a second-line therapy for the treatment of patients with unresectable or metastatic melanoma.